AI in Healthcare

Today's Stories

1. 1

   Intuitive Surgical unveils five-layer AI framework, demos live telesurgery

   Intuitive Surgical revealed a five-layer AI framework for its surgical platforms and demonstrated a live real-time telesurgical collaboration across distant facilities, showing how it plans to integrate AI into clinical workflows rather than as a standalone feature. The roadmap may influence how hospitals and surgeons adopt AI in surgery, shape partnerships, and affect investor views of Intuitive Surgical's long-term positioning in computer-assisted surgery—particularly as the stock has fallen 40.9% year to date and faces pressure.

   Hospital responses in terms of system placements, procedure volumes, and any disclosed AI-related service revenue in coming quarters; execution risks include regulatory comfort, data security, and surgeon adoption for AI-assisted and remote procedures.

2. 2

   Cigna deploys AI to scale care management program

   Cigna is using AI to expand its care management program, leveraging the technology to reach and support more patients across its member base. Care management programs help patients navigate complex health needs and reduce unnecessary medical costs. By using AI, Cigna can automate routine tasks and allocate human staff more efficiently to cases requiring personal attention, potentially improving outcomes while controlling expenses.

   The article does not specify a timeline, target enrollment, cost savings goal, or rollout regions, so concrete metrics on program scale and impact are not yet available.

3. 3

   Merck KGaA's AI Chief: Models Aren't the Advantage—Context and Trust Are

   Walid Mehanna, chief data and A.I. officer at Germany's Merck KGaA (the world's oldest pharmaceutical company, founded in the 17th century), is guiding the company's 62,000 employees through a three-layer A.I. strategy: everyday tools for productivity, embedded A.I. in core workflows like R&D and supply chains, and eventually product A.I. for drug discovery. The company deployed an internal platform called MyGPT in June 2023, then replaced it within a year by partnering with LangDock, a Berlin-based startup, to build a GDPR-compliant, model-agnostic system hosted in its own environment. Mehanna has shifted from believing the competitive edge lies in foundational models to holding that durable advantage comes from an organization's data, processes, workforce fluency, and customer trust—a view that challenges the assumption that the "best model" will win. For enterprises, this means the infrastructure and governance layer (not just the AI vendor) determines success; Merck KGaA's approach to privacy-protected A.I. (analyzing over 12 million internally-generated prompts at an aggregate level only, never monitoring individuals) shows how companies can move fast while meeting strict European regulation and labor relations requirements.

   Mehanna's Digital Ethics Advisory Panel, guided by five principles (autonomy, beneficence, non-maleficence, justice, and transparency), pushes teams to identify risks and design safeguards before launch rather than simply approving or rejecting projects. Teams now integrate data incrementally (process by process) rather than via a company-wide semantic layer, reflecting a matured view of how to scale A.I. across a large, regulated enterprise.

4. 4

   AlphaFold redesigns CRISPR proteins to cut gene-editing errors

   Researchers used Google's AlphaFold AI to identify which parts of Cas9 proteins enable off-target DNA edits in CRISPR gene-editing systems. They then modified those specific amino acid positions—making 23 different swaps across 10 key sites—and created a variant that reduced off-target activity from 28 percent to 5 percent while maintaining normal activity at intended target sites. Gene-editing therapies must edit many cells to be effective, making even rare off-target errors inevitable at scale. Current approaches rely on guide RNA design or protein evolution to minimize mistakes. This work offers a new method: using AI to predict exactly which parts of the Cas9 protein cause mismatch tolerance, then redesigning them—potentially making therapies safer and unlocking clinical applications where off-target effects were a bottleneck.

   The approach appears adaptable to other Cas proteins (the team tested it with Cas12) and may be combinable with existing improved Cas9 variants developed through other methods, though that combination was not tested. The method could also extend beyond gene editing to fine-tune other protein-DNA interactions.

5. 5

   AI diagnostic aid shows promise but study too small to prove patient benefit

   Researchers tested AI Consult, a tool powered by OpenAI's GPT-4o that flags potential clinical issues, in a randomized trial of nearly 10,000 patient encounters across 16 Kenyan primary care clinics. An independent panel of six Kenyan family physicians judged that clinicians using the AI produced better diagnoses and treatment plans, and the tool cost 4 cents per patient. Results were published this summer in Nature Medicine. The trial captured both the potential of AI to improve healthcare in lower-resource settings and the challenge of proving it works. Although health workers found the AI checkup helpful, the study did not find statistically significant evidence of improved patient outcomes — treatment failures decreased by 23% but the sample was too small. Dr. Bilal Mateen, a co-author and chief AI officer at PATH, says a trial would need about 139,000 people to detect a meaningful difference. For clinicians like Vyonne Njeri, a registered clinical officer in Nairobi who sees five or six patients an hour without specialist backup, the tool offers practical value as a safety check on diagnoses.

   Dr. Jonathan Chen at Stanford notes this is among the first trials to compare this type of AI's role in primary care beyond simulated tests, and calls it important. Mateen says he is working toward implementing the tool globally. However, healthcare AI researcher Dr. Nicholas Okumu warns that even AI systems that are approved can still cause harm, so oversight must remain active.

6. 6

   Innovaccer hits $200M ARR by fixing hospitals' fragmented data

   Innovaccer, a healthcare data platform founded by Abhinav Shashank, crossed $200 million（約320億円） in annual recurring revenue (up from roughly $130 million（約210億円） last year). The company pulls data from hospitals' electronic health records and insurance claims systems, unifies it, and makes it usable for AI tools and care coordination. Gartner named it a leader in its first-ever healthcare technology Magic Quadrant this week, ranking it above Microsoft, Google, AWS, and Salesforce on vision and execution. U.S. healthcare spending will top $6 trillion（約960兆円） this year, with $1.5 trillion（約240兆円） of it pure administrative waste, according to Shashank's estimate. Innovaccer's customers reported roughly $2.5 billion（約4000億円） in savings to federal regulators last year alone, mostly from care coordination. The company works with seven of the top ten U.S. health systems across 80 million patient records, addressing a core problem: without unified data infrastructure, AI companies are 'trying to put cars on a road that does not exist,' as Shashank puts it.

   Innovaccer has raised $675 million（約1100億円） total, including a $275 million（約440億円） round last year from B Capital, Danaher Ventures, Generation Investment Management, Kaiser Permanente, and Microsoft's M12. The company's thesis is a decade of unglamorous plumbing—building the data infrastructure that connects hospitals' locked-up electronic health records and insurance claims systems.